Table 2.

Characteristics of COVID-19 patients infected with Marseille-2 (B.1.177 lineage) and Marseille-4 (B.1.160 lineage) variants during the second phase of the epidemic in Marseille (univariate and multivariate analysis).

	B.1.177		B.1.160		B.1.177 vs. B.1.160
	n	%	n	%	Univariate analysis OR [95% CI]; P-value	Multivariate analysis OR [95% CI]; P-value
	N = 69		N = 281		Ref = B.1.160
Sociodemographic characteristic
Mean age	56.0 ± 21.6		58.3 ± 23.1		NA	NA
Age
<45	24	34.8	74	26.3	ref	ref
45–64	19	27.5	88	31.3	0.67 [0.34–1.31]; 0.24	NA
≥65	26	37.7	119	42.4	0.67 [0.36–1.26]; 0.22	NA
Gender
Female	38	55.1	127	45.2	0.67 [0.38–1.18]; 0.14	–
Male	31	44.9	154	54.8
Hypertension	17	24.6	86	30.6	0.74 [0.38–1.39]; 0.33	NA
Diabetes	5	7.3	49	17.4	0.37 [0.11–0.98]; 0.04	–
Cancer	8	11.6	27	9.6	1.23 [0.46–2.97]; 0.62	NA
Chronic respiratory disease	5	7.3	37	13.2	0.52 [0.15–1.39]; 0.18	–
Chronic heart disease	14	20.3	55	19.6	1.05 [0.50–2.08]; 0.89	NA
Obesity	8	11.6	27	9.6	1.23 [0.46–2.97]; 0.62	NA
Clinical signs
Fever	27	39.1	121	43.1	0.85 [0.48–1.50]; 0.55	NA
Cough	28	40.6	106	37.7	1.13 [0.63–1.99]; 0.66	NA
Rhinitis	10	14.5	45	16.0	0.89 [0.38–1.92]; 0.76	NA
Dyspnoea	17	24.6	71	25.3	0.97 [0.49–1.83]; 0.91	NA
Anosmia	11	15.9	39	13.9	1.17 [0.51–2.51]; 0.67	NA
Ageusia	9	13.0	38	13.6	0.96 [0.38–2.15]; 0.91	NA
Hypoxemia	17	24.6	86	30.6	0.74 [0.38–1.39]; 0.33	NA
Clinical outcomes
Hospitalisation	21	30.4	129	45.9	0.52 [0.28–0.93]; 0.02	0.52 [0.29–0.91]; 0.02
ICU	2	2.9	16	5.7	0.49 [0.05–2.19]; 0.35	NA
Death	8	11.6	44	15.7	0.71 [0.27–1.62]; 0.40	NA

Ref: reference, NA: not applicable, −: non-significant.